Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $9.10 in the prior trading day, EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) closed at $9.08, down -0.22%. In other words, the price has decreased by -$0.22 from its previous closing price. On the day, 0.61 million shares were traded. EYPT stock price reached its highest trading level at $9.18 during the session, while it also had its lowest trading level at $8.78.
Ratios:
Our goal is to gain a better understanding of EYPT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.01 and its Current Ratio is at 5.08. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JP Morgan on January 22, 2024, initiated with a Overweight rating and assigned the stock a target price of $35.
On November 02, 2023, Mizuho started tracking the stock assigning a Buy rating and target price of $20.
On April 21, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $33.Robert W. Baird initiated its Outperform rating on April 21, 2023, with a $33 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 03 ’24 when GUYER DAVID R sold 11,625 shares for $10.30 per share. The transaction valued at 119,705 led to the insider holds 3,700 shares of the business.
GUYER DAVID R sold 11,625 shares of EYPT for $147,045 on May 14 ’24. The Director now owns 5,550 shares after completing the transaction at $12.65 per share. On May 06 ’24, another insider, Cormorant Asset Management, LP, who serves as the 10% Owner of the company, bought 850,000 shares for $11.86 each. As a result, the insider paid 10,081,721 and bolstered with 8,325,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EYPT now has a Market Capitalization of 472926336 and an Enterprise Value of 179300128. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.45 while its Price-to-Book (P/B) ratio in mrq is 1.81. Its current Enterprise Value per Revenue stands at 3.585 whereas that against EBITDA is -2.11.
Stock Price History:
Over the past 52 weeks, EYPT has reached a high of $30.99, while it has fallen to a 52-week low of $5.67. The 50-Day Moving Average of the stock is -41.60%, while the 200-Day Moving Average is calculated to be -43.92%.
Shares Statistics:
The stock has traded on average 1.15M shares per day over the past 3-months and 1172030 shares per day over the last 10 days, according to various share statistics. A total of 49.04M shares are outstanding, with a floating share count of 49.00M. Insiders hold about 5.93% of the company’s shares, while institutions hold 105.20% stake in the company. Shares short for EYPT as of 1715731200 were 8134745 with a Short Ratio of 7.05, compared to 1713139200 on 6536042. Therefore, it implies a Short% of Shares Outstanding of 8134745 and a Short% of Float of 18.4.
Earnings Estimates
The stock of EyePoint Pharmaceuticals Inc (EYPT) is currently drawing attention from 10.0 analysts actively involved in the ongoing evaluation and rating process.On average, analysts expect EPS of -$0.52 for the current quarter, with a high estimate of -$0.34 and a low estimate of -$0.66, while EPS last year was -$0.61. The consensus estimate for the next quarter is -$0.58, with high estimates of -$0.44 and low estimates of -$0.76.
Analysts are recommending an EPS of between -$1.86 and -$2.86 for the fiscal current year, implying an average EPS of -$2.33. EPS for the following year is -$3.1, with 10.0 analysts recommending between -$2.32 and -$4.55.
